Last reviewed · How we verify
NCT02854345: PARAT-CZT
Preliminary Study Concerning the Validity of Parathyroid Exploration on a CZT Camera
NA trial testing Tomoscintigraphic parathyroid imaging on a CZT camera in Primary Hyperparathyroidism in 45 participants. Completed in 9 September 2021.
9 September 2021
Quick facts
| Lead sponsor | Centre Hospitalier Universitaire de Besancon |
|---|---|
| Phase | NA |
| Status | Completed |
| Study type | INTERVENTIONAL |
| Allocation | na |
| Design | single group |
| Masking | none |
| Primary purpose | diagnostic |
| Enrollment | 45 |
| Start date | 4 September 2014 |
| Primary completion | 9 September 2021 |
| Estimated completion | 9 September 2021 |
| Sites | 1 location across France |
Drugs / interventions tested
- Tomoscintigraphic parathyroid imaging on a CZT camera
Conditions studied
- Primary Hyperparathyroidism — all drugs for Primary Hyperparathyroidism →
Sponsor
Centre Hospitalier Universitaire de Besancon
Who can join
Adults 18 to 80, any sex, with Primary Hyperparathyroidism. Patients with the condition only — healthy volunteers not accepted.
Sponsor's own description
The goal of this study is to assess the performance of parathyroid imaging on a cardiac-dedicated CZT camera, compared to planar pinhole imaging, in patients referred for primary hyperparathyroidism.
Publications & conference data
No peer-reviewed publications indexed yet for this trial. Completed trials usually publish results within 12-18 months.
Verify or expand the search:
- PubMed search for NCT02854345
- Europe PMC full search
- ASCO Meeting Library
- ESMO Meeting Library
- bioRxiv preprints
- medRxiv preprints
- Google Scholar
Related trials
Other recruiting trials for Primary Hyperparathyroidism
Currently open trials in the same condition.
- NCT07444723 — Accuracy of 18F-Fluorocholine PET/MR and NeuroEXPLORER PET/CT Imaging for Localization of Parathyroid Tumors · Phase 2, PHASE3 · recruiting
- NCT06859580 — Bisphosphonate Prior to Parathyroidectomy in Primary Hyperparathyroidism · Phase 4 · recruiting
- NCT05997810 — Parathyroid Tumor Clonal Status · recruiting
- NCT05761743 — Glycemic Control, Type II Diabetes, Parathyroidectomy · active not recruiting
- NCT07138820 — 18F-choline Positron-emission-tomography - Computed-tomography Compared to Conventional Imaging for Localizing Diseased · NA · recruiting
Other Centre Hospitalier Universitaire de Besancon trials
Trials by the same sponsor.
- NCT07492199 — High Depth Exome Sequencing on DNA From a Salivary Sample by Mouth Smear. · not yet recruiting
- NCT07438015 — VEXUS-REA : Evaluation of Ultrasound Parameters of Venous Congestion in Patients in a Medical Intensive Care Unit · NA · not yet recruiting
- NCT06796114 — Identification of Innovative Biomarkers to Predict Outcomes in Hepatocellular Carcinoma Treated With Tremelimumab and Du · NA · recruiting
- NCT06864065 — Study of Emotional Regulation and Underlying Prefrontal Activity in Binge Eating Disorder · NA · recruiting
- NCT07067762 — Botulinum Toxin Injections Into the Salivary Glands of Cerebrospinal Children With Chronic Sialorrhea · completed
Verify against primary sources
- ClinicalTrials.gov — authoritative US registry record
- WHO ICTRP — international registry index
- EU Clinical Trials Register
- Sponsor press releases (Google)
- Trial protocol + status: ClinicalTrials.gov NCT02854345 (US National Library of Medicine, public domain)
- Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
- Sponsor: as reported to ClinicalTrials.gov by Centre Hospitalier Universitaire de Besancon
- Last refreshed: 19 September 2024
Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT02854345.
Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing